Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
07 October 1983Website:
http://www.anixa.comNext earnings report:
12 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 19:15:32 GMTDividend
Analysts recommendations
Institutional Ownership
ANIX Latest News
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company specializing in cancer treatment and prevention, will be participating in the Sidoti Micro-Cap Virtual Conference on May 8-9, 2024.
Some of the most explosive opportunities can be found in biotech stocks. Look at CRISPR Therapeutics (NASDAQ: CRSP ), for example.
FATE reports better-than-expected third-quarter 2023 financial results, driven by lower operating expenses. The stock rises about 5% in the after-market hours.
ANIXA BIOSCIENCES INC (ANIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The United States Treasury Secretary, Janet Yellen, recently expressed her confidence in the economy's ability to recover from the recession without causing significant harm to the job market or sparking excessive inflation. She believes that the United States will successfully navigate this economic challenge, maintaining control over consumer-price increases.This is leading to many investors considering cheap stocks to buy.
ANIXA BIOSCIENCES INC (ANIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here is how ANIXA BIOSCIENCES INC (ANIX) and Intuitive Surgical, Inc. (ISRG) have performed compared to their sector so far this year.
Anixa: I Am More Bullish After Efficacy Data For Its Triple-Negative Breast Cancer Vaccine
Anixa Biosciences (ANIX) announces positive top-line data from its phase Ia study evaluating the safety of its breast cancer vaccine. However, the stock plunges 25% in the absence of efficacy reports.
What type of business is Anixa Biosciences?
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
What sector is Anixa Biosciences in?
Anixa Biosciences is in the Healthcare sector
What industry is Anixa Biosciences in?
Anixa Biosciences is in the Biotechnology industry
What country is Anixa Biosciences from?
Anixa Biosciences is headquartered in United States
When did Anixa Biosciences go public?
Anixa Biosciences initial public offering (IPO) was on 07 October 1983
What is Anixa Biosciences website?
https://www.anixa.com
Is Anixa Biosciences in the S&P 500?
No, Anixa Biosciences is not included in the S&P 500 index
Is Anixa Biosciences in the NASDAQ 100?
No, Anixa Biosciences is not included in the NASDAQ 100 index
Is Anixa Biosciences in the Dow Jones?
No, Anixa Biosciences is not included in the Dow Jones index
When does Anixa Biosciences report earnings?
The next expected earnings date for Anixa Biosciences is 12 March 2025